Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Breakthrough In Treatment For Kidney Dialysis Patients

13.08.2004


A ground-breaking medical approach which could substantially improve the quality of life for over a million kidney dialysis patients, and bring huge savings to health services around the globe, is one step closer to becoming a reality, thanks to NESTA (the National Endowment of Science, Technology and the Arts) – the organisation that backs UK innovation.

NESTA has invested £95,000 in a university spin-out, Veryan Medical Limited, based at London’s Imperial College, to further develop their ground-breaking approach. The company has been financed to date by NPI Ventures Limited and Imperial College Innovations.

Veryan are dedicated to developing a number of novel medical devices to address urgent, unmet medical needs in the field of vascular disease, the greatest cause of death in the modern world. Their inventions are designed to recreate the natural swirling fluid flow of the body and prevent the development of disease. The first device to be tested in clinical human trials will be the SwirlGraft™ vascular access graft.



Currently, there are over one million people requiring regular connection to a kidney dialysis machine in order to sustain their lives. A majority of these patients have a synthetic vessel, called a vascular access graft, inserted beneath the skin to facilitate regular hypodermic puncturing and to maximize blood-flow to the dialysis machine. However, these grafts typically develop a potentially lethal disease, called ‘intimal hyperplasia’, which can block the downstream junction with the natural vessel in just a few months. This results in most grafts requiring replacement within a year, and many patients require remedial surgery up to three times a year.

SwirlGraft™ has the potential to be the most effective solution to this problem. By ensuring appropriate swirling blood flow through the dialysis graft and into the downstream vein, it stands to greatly reduce the disease by eliminating the stagnant flow regions where intimal hyperplasia proliferates.

The SwirlGraft™ device has been developed by Professor Colin Caro at Imperial College, and comes on the back of research dating back to 1966. Professor Caro is considered to be a world expert on the links between the physics of blood flow and disease. Veryan Medical is headed up by Philip Birch who brings substantial expertise of building and funding early stage healthcare companies.

NESTA’s investment will be used to develop the SwirlGraft™ device from the current experimental proof of concept through to clinical proof of concept. The trials will be based in the Netherlands and will involve 25 dialysis patients fitted with SwirlGraft™ for their vascular access, monitored for a year.

Mark White, NESTA’s Invention and Innovation Director, said: “We are delighted to be investing in a product which meets an urgent need for improved clinical performance, as well as bringing huge benefits to dialysis patients from around the world.”

| alfa
Further information:
http://www.nesta.org.uk

More articles from Health and Medicine:

nachricht Finding new clues to brain cancer treatment
21.02.2020 | Case Western Reserve University

nachricht UIC researchers find unique organ-specific signature profiles for blood vessel cells
18.02.2020 | University of Illinois at Chicago

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A step towards controlling spin-dependent petahertz electronics by material defects

The operational speed of semiconductors in various electronic and optoelectronic devices is limited to several gigahertz (a billion oscillations per second). This constrains the upper limit of the operational speed of computing. Now researchers from the Max Planck Institute for the Structure and Dynamics of Matter in Hamburg, Germany, and the Indian Institute of Technology in Bombay have explained how these processes can be sped up through the use of light waves and defected solid materials.

Light waves perform several hundred trillion oscillations per second. Hence, it is natural to envision employing light oscillations to drive the electronic...

Im Focus: Freiburg researcher investigate the origins of surface texture

Most natural and artificial surfaces are rough: metals and even glasses that appear smooth to the naked eye can look like jagged mountain ranges under the microscope. There is currently no uniform theory about the origin of this roughness despite it being observed on all scales, from the atomic to the tectonic. Scientists suspect that the rough surface is formed by irreversible plastic deformation that occurs in many processes of mechanical machining of components such as milling.

Prof. Dr. Lars Pastewka from the Simulation group at the Department of Microsystems Engineering at the University of Freiburg and his team have simulated such...

Im Focus: Skyrmions like it hot: Spin structures are controllable even at high temperatures

Investigation of the temperature dependence of the skyrmion Hall effect reveals further insights into possible new data storage devices

The joint research project of Johannes Gutenberg University Mainz (JGU) and the Massachusetts Institute of Technology (MIT) that had previously demonstrated...

Im Focus: Making the internet more energy efficient through systemic optimization

Researchers at Chalmers University of Technology, Sweden, recently completed a 5-year research project looking at how to make fibre optic communications systems more energy efficient. Among their proposals are smart, error-correcting data chip circuits, which they refined to be 10 times less energy consumptive. The project has yielded several scientific articles, in publications including Nature Communications.

Streaming films and music, scrolling through social media, and using cloud-based storage services are everyday activities now.

Im Focus: New synthesis methods enhance 3D chemical space for drug discovery

After helping develop a new approach for organic synthesis -- carbon-hydrogen functionalization -- scientists at Emory University are now showing how this approach may apply to drug discovery. Nature Catalysis published their most recent work -- a streamlined process for making a three-dimensional scaffold of keen interest to the pharmaceutical industry.

"Our tools open up whole new chemical space for potential drug targets," says Huw Davies, Emory professor of organic chemistry and senior author of the paper.

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

70th Lindau Nobel Laureate Meeting: Around 70 Laureates set to meet with young scientists from approx. 100 countries

12.02.2020 | Event News

11th Advanced Battery Power Conference, March 24-25, 2020 in Münster/Germany

16.01.2020 | Event News

Laser Colloquium Hydrogen LKH2: fast and reliable fuel cell manufacturing

15.01.2020 | Event News

 
Latest News

Active droplets

21.02.2020 | Medical Engineering

Finding new clues to brain cancer treatment

21.02.2020 | Health and Medicine

Beyond the brim, Sombrero Galaxy's halo suggests turbulent past

21.02.2020 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>